Skip to main content
Clinical Trials/NCT06368635
NCT06368635
Recruiting
Not Applicable

The Cerebral Microcirculation Diseases and Coronary Microcirculation Disease Study(CCMD)

Weijing Wang1 site in 1 country100 target enrollmentJanuary 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Microcirculation
Sponsor
Weijing Wang
Enrollment
100
Locations
1
Primary Endpoint
MACE
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Ischaemic heart disease (IHD) and degenerative brain disease are two major sources of death and disability affecting all countries. While the consequences of obstructive disease in major vessels supplying blood to both organs have been widely documented, less attention has been paid to disease processes affecting the microcirculation that may affect cardiac and cerebral function. Yet, over the last decade significant progress has been made in understanding the substrate of microvascular disease in both organs. In the heart, arteriolar thickening and capillary rarefaction that reduce the conductance of the microvasculature and its ability to vasodilate in response to increased myocardial oxygen demands constitute the leading cause of coronary microvascular dysfunction (CMD). In the brain, concentric hyaline thickening of deep penetrating small arteries (arteriolosclerosis) with associated fibrosis of the vessel wall constitutes the most frequent substrate for cerebral small vessel disease (CSVD). Of note, both CMD and CSVD share common risk factors, such as age, hypertension, and diabetes.3 These factors might have a common effect on the microvascular domain of cardiac and cerebral vascular beds.

Although a potential link between both conditions has been hypothesized based on the similarities between pathological changes and risk factors, advance in knowledge exploring this has been hampered by lacking objective evidence of CMD and pathological brain changes indicative of CSVD in prior research studies. Thus, the relationship between CMD and CSVD is unknown.

The main objective of this study was to analyse the relationship between cerebrovascular disease and CMD in patients with atherosclerotic coronary artery disease (CAD).

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
March 31, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Weijing Wang
Responsible Party
Sponsor Investigator
Principal Investigator

Weijing Wang

Principal Investigator

China National Center for Cardiovascular Diseases

Eligibility Criteria

Inclusion Criteria

  • Informed Consent available.
  • Age 45-80 years.
  • Stable coronary lesions.
  • target vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR ≥0.8; or severe stenosis(\>80%)after successful PCI and FFR ≥0.8

Exclusion Criteria

  • Previous myocardial infarction in the territory of distribution of the target vessel.
  • Aortic valve stenosis (moderate or severe) .
  • Severe left ventricle hypertrophy.
  • Left ventricle moderate systolic dysfunction (EF \< 35%).
  • Contraindications to adenosine.
  • Previous CABG (Coronary artery bypass grafting) with permeable grafts.
  • Contraindication to stent implantation.
  • Severe anemia.
  • Unilateral or bilateral carotid artery stenosis (\> 50%).
  • Unilateral or bilateral middle cerebral arteries (\>50%).

Outcomes

Primary Outcomes

MACE

Time Frame: 12 month

Incidence of Major Cardiovascular Events (MACE): all-cause of death, myocardial infarction and any type of coronary revascularization

Secondary Outcomes

  • Cerebral microcirculation(12 month)

Study Sites (1)

Loading locations...

Similar Trials